Preview

Translational Medicine

Advanced search

Concentration omentin-1 in the serum of patients with coronary heart disease

https://doi.org/10.18705/2311-4495-2019-6-6-5-13

Abstract

Background. Omentin-1 (QM-1) — one of the most important anti-inflammatory adipocytokines produced by adipose tissue. It is known that its concentration is reduced in obese patients. However, the role of OM-\ in the pathogenesis of coronary heart disease (CHD), including acute coronary syndrome (ACS), is not fully determined.

The objective of the study — to assess the level of OM-1 in blood serum of patients with ACS without ST-segment elevation (ACSWEST) who underwent percutaneous coronary intervention (PCI) and patients with stable CHD.

Design and methods. Examined 104 patients with ACSWEST undergoing PCI. Comparison groups consisted of 38 patients without CHD according negative results of stress-echocardiography or coronary angiography, as well as 80 patients with stable CHD. All patients were evaluated anthropometric indicators: height, weight, waist circumference (WC), body mass index (BMI). Serum concentrations of OM-I were determined by enzyme immunoassay (DRG,USA), serum lipid profile was determined by enzymatic method.

Results. In patients with ACSWEST who underwent PCI, the concentration of OM-I in the blood is lower than in those examined without atherosclerotic lesions of the coronary arteries [7.53 (5.00-10.55) ng/ml and 12.56 (7.84-15.34) ng/ml, respectively; p < 0.001). The concentration of OM-1 in the blood in patients with ACSWEST and a stable CHD did not differ (p > 0.05). In patients with ACSWEST, the concentration of OM-1 blood with multivascular lesions of the coronary arteries is lower than with 1-2 vascular lesions [7.30 (3.91- 8.17) ng/ml and 9.44 (6.54-9.93) ng/ml, respectively; p < 0.001. Similar patterns were established in patients with a stable CHD (p < 0.001).

The concentration of OM-1 inthe blood in women with ACSWEST, with stable CHD and in those examined without CHD was higher than in men of the corresponding groups (p < 0.001).

In patients with ACSWEST and with a stable CHD with overweight and obesity (WHO, 1999), the concentration of OM-1 inblood serum is lower than in patients with CHD and normal BMI (p < 0.001). In patients with ACSWEST and AO, the level of OM-1 inthe blood is lower than in patients with ACSWEST without AO, both in men and women (p < 0.001). When conducting a regression analysis, it was found that the concentration of OM-1 inthe blood of patients with ACSWEST is determined by BMI (b = -0.30, beta = -0.23, p = 0.002) and patient gender (b = 2.21, beta = 0.16, p = 0.029); in patients with a stable CHD — BMI (b = -0.38, beta = -0.27, p = 0.029).

Conclusion. For patients with CHD, both with ACSWEST and with stable CHD, a low level of OM-1 in the blood is characteristic. The lowest OM-1 values were found in patients with multivascular coronary artery disease and obesity. The gender characteristics of the concentration of OM-1 in serum were established: the concentration of OM-1 in serum in women is higher than in men. A decrease in the concentration of OM-1 in the blood in patients with ACSWEST and with stable CHD is associated with BMI, the patient’s gender, and the severity of coronary atherosclerosis.

About the Authors

A. S. Draganova
Federal State Budgetary Education Institution of Higher Education «Academician I. P. Pavlov First Saint Petersburg State Medical University» of Ministry of Healthcare of the Russian Federation; Almazov National Medical Research Centre

Draganova Anna S., MD, PhD Student, Department of Therapy № 2 with the Coarse of Endocrinology, Cardiology and Functional Diagnostics, FSBEI HE I. P. Pavlov SPbSMU MOH Russia

L’va Tolstogo str. 6/8, Saint Petersburg, Russia, 197022



E. A. Polyakova
Federal State Budgetary Education Institution of Higher Education «Academician I. P. Pavlov First Saint Petersburg State Medical University» of Ministry of Healthcare of the Russian Federation; Almazov National Medical Research Centre

Polyakova Ekaterirra A., MD, PhD, Assistant, Department of Therapy № 2 with the Course of Endocrinology, Cardiology and Functional Diagnostics; Researcher, Laboratory for Hypertension, Research Institution of Cardiovascular Diseases, FSBEI HE 1. P. Pavlov SPbSMU MOH Russia; Researcher, Laboratory of metabolic syndrome, Almazov National Medical Research Centre

Saint Petersburg



D. A. Kolodina
Federal State Budgetary Education Institution of Higher Education «Academician I. P. Pavlov First Saint Petersburg State Medical University» of Ministry of Healthcare of the Russian Federation

Kolodina Diana A., MD, Assistant, Department of Therapy № 2 with the Course of Endocrinology, Cardiology and Functional Diagnostics

Saint Petersburg



О. D. Belyaeva
Federal State Budgetary Education Institution of Higher Education «Academician I. P. Pavlov First Saint Petersburg State Medical University» of Ministry of Healthcare of the Russian Federation; Almazov National Medical Research Centre

Belyaeva Olga D., MD, PhD, Dr. Sc., Professor, Department of Therapy № 2 with the Course of Endocrinology, Cardiology and Functional Diagnostics; Head of Laboratory for Hypertension, Research Institution for Cardiovascular Diseases, Research Medical Scientific Centre, FSBEI HE 1. P. Pavlov SPbSMU MOH Russia

Saint Petersburg



О. A. Berkovich
Federal State Budgetary Education Institution of Higher Education «Academician I. P. Pavlov First Saint Petersburg State Medical University» of Ministry of Healthcare of the Russian Federation; Almazov National Medical Research Centre

Berkovich Olga A., MD, PhD, Dr. Sc., Professor, Department of Therapy №2 with the Course of Endocrinology, Cardiology and Functional Diagnostics; Head of Laboratory for Coronary Heart Disease, Research Institution for Cardiovascular Diseases, Research Medical Scientific Centre, FSBEI HE 1. P. Pavlov SPbSMU MOH Russia

Saint Petersburg



T. L. Karonova
Almazov National Medical Research Centre

Karonova Tatyana L., MD, PhD, Dr. Sc., Professor, Department of Therapy №2 with the Course of Endocrinology, Cardiology and Functional Diagnostics, Head of Research Laboratory of Clinical Endocrinology, Almazov National Medical Research Centre

Saint Petersburg



E. V. Shlyakhto
Federal State Budgetary Education Institution of Higher Education «Academician I. P. Pavlov First Saint Petersburg State Medical University» of Ministry of Healthcare of the Russian Federation; Almazov National Medical Research Centre

Shlyakhto Evgeny Y, MD, PhD, Dr. Sc., Professor, Head of Department of Therapy №2 with the Course of Endocrinology, Cardiology and Functional Diagnostics, FSBEI HE I. P. Pavlov SPbSMU MOH Russia; Director of Almazov National Medical Research Centre

Saint Petersburg



References

1. Artamonova GV, Maksimov SA, Tabakaev MV et al. A rank-order method for the integrated assessment of trends in all-cause and cardiovascular mortality rates in the subjects of the Russian Federation in 2006- 2012. Terapevticheskij arhiv=Therapeutic archive. 2016;88(1):11-16. In Russian

2. Muromtseva GA, Kontsevaya AV, Konstantinov VV et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012–2013 years. The results of ECVDRF. Kardiovaskulyarnaya terapiya i profilaktika=Cardiovascular therapy and prevention. 2014; 13 (6): 4–11. In Russian.

3. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol. 2013;216(1):T17–36.

4. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010;88(1):29–33.

5. Li ХP, Zeng S, Wang M et al. Relationships between serum omentin-1, body fat mass and bone mineral density in healthy Chinese male adults in Changsha area. J Endocrinol Invest. 2014;37(10):991–1000.

6. Yamawaki H, Tsubaki N, Mukohda M et al. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun. 2010;393(4):668–672.

7. Maruyama S, Shibata R, Kikuchi R et al. Fatderived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem. 2012;287(1):408–417.

8. Kadoglou NP, Tahmatzidis DK, Giannakoulas C et al. Serum levels of novel adipokines, omentin-1 and chemerin, in patients with acute myocardial infarction: KOZANI STUDY. J Cardiovasc Med (Hagerstown). 2015;16(5):341–346.

9. Saely CH, Leiherer A, Muendlein A et al. Coronary patients with high plasma omentin are at a higher cardiovascular risk. Data Brief. 2015;6:158–161.

10. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)1; European Association for Percutaneous Cardiovascular Interventions (EAPCI) et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2501–2555.

11. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Rossijskij kardiologicheskij zhurnal=Russian Journal of Cardiology. 2016;3(131):9–63. In Russian.

12. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–1701.

13. Antonio de Luis D, Izaola O, Primo D et al. Modifications of serum levels of omentin-1 and other cardiovascular risk factors following weight loss secondary to a Mediterranean hypocaloric diet. Clin Nutr. 2018;37(6 PtA):2280–2283.

14. Herder С, Ouwens DM, Carstensen M et al. Аdiponectin may mediate the association between omentin, circulating lipids and insulin sensitivity: results from the KORA F4 study. Eur J Endocrinol. 2015;172(4):423–432.

15. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev. 2007;27(7):762–778. 16. Scherer PE. The multifaceted roles of adipose tissue — therapeutic targets for diabetes and beyond: the 2015 Banting lecture. Diabetes. 2016;65(6):1452–1461.

16. Stejskal D, Vaclavik J, Smekal A et al. Omentin-1 levels in patients with premature coronary artery disease, metabolic syndrome and healthy controls. Short communication. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(2):219–221.

17. Saely CH, Leiherer A, Muendlein A et al. High plasma omentin predicts cardiovascular events independently from the presence and extent of angiographically determined atherosclerosis. Atherosclerosis. 2016;244:38–43.

18. Tsuji S, Uehori J, Matsumoto M et al. Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem. 2001;276(26):23456–23463.

19. Zabetian-Targhi F, Mirzaei K, Keshavarz SA et al. Modulatory role of omentin-1 in inflammation: cytokines and dietary intake. J Am Coll Nutr. 2016;35(8):670–678.

20. Martínez-García MÁ, Montes-Nieto R, Fernández-Durán E et al. Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 2013;98(2):E388–396.

21. Panagiotou G, Mu L, Na B et al. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism. 2014;63(10):1265–1271.

22. de Luis DA, García Calvo S, Lopez Gomez JJ et al. Omentin-1 changes following biliopancreatic diversion and relationship with cardiovascular risk factors. Ann Nutr Metab. 2018;73(2):106–112.

23. Menzel J, di Giuseppe R, Biemann R et al. Association between chemerin, omentin-1 and risk of heart failure in the population-based EPIC-Potsdam study. Sci Rep. 2017;7(1):14171.

24. Motawi TMK, Mahdy SG, El-Sawalhi MM et al. Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis. Can J Physiol Pharmacol. 2018;96(1):38–44.

25. Du Y, Ji Q, Cai L et al. Association between omentin-1 expression in human epicardial adipose tissue and coronary atherosclerosis. Cardiovasc Diabetol. 2016;15:90.

26. Harada K, Shibata R, Ouchi N et al. Increased expression of the adipocytokine omentin in the epicardial adipose tissue of coronary artery disease patients. Atherosclerosis. 2016;251:299–304.

27. Kadoglou NP, Lambadiari V, Gastounioti A et al. The relationship of novel adipokines, RBP4 and omentin-1, with carotid atherosclerosis severity and vulnerability. Atherosclerosis. 2014;235(2):606–612.

28. Xu T, Zuo P, Cao L et al. Omentin-1 is associated with carotid plaque instability among ischemic stroke patients. J Atheroscler Thromb. 2018;25(6):505–511.

29. Zhong Х, Zhang НY, Тan Н et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011;32(7):873–878.

30. Saddic LA, Nicoloro SM, Gupta OT et al. Joint analysis of left ventricular expression and circulating plasma levels of Omentin after myocardial ischemia. Cardiovasc Diabetol. 2017;16(1):87.

31. Smékal A, Václavík J, Stejskal D et al. Plasma levels and leucocyte RNA expression of adipokines in young patients with coronary artery disease, in metabolic syndrome and healthy controls. Cytokine. 2019;122:154017.

32. Zhou JP, Tong XY, Zhu LP et al. Plasma omentin-1 level as a predictor of good coronary collateral circulation. J Atheroscler Thromb.2017;24(9):940–948.


Review

For citations:


Draganova A.S., Polyakova E.A., Kolodina D.A., Belyaeva О.D., Berkovich О.A., Karonova T.L., Shlyakhto E.V. Concentration omentin-1 in the serum of patients with coronary heart disease. Translational Medicine. 2019;6(6):5-13. (In Russ.) https://doi.org/10.18705/2311-4495-2019-6-6-5-13

Views: 1384


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2311-4495 (Print)
ISSN 2410-5155 (Online)